A5061594462- Cystic Fibrosis Research Advances
- Tracheal and airway disorders
- Neonatal Respiratory Health Research
- Pediatric health and respiratory diseases
- Respiratory viral infections research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Dysphagia Assessment and Management
- Respiratory and Cough-Related Research
- Pneumonia and Respiratory Infections
- Immunodeficiency and Autoimmune Disorders
- Neuroscience and Neuropharmacology Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Pneumocystis jirovecii pneumonia detection and treatment
- Childhood Cancer Survivors' Quality of Life
- Esophageal and GI Pathology
- Inhalation and Respiratory Drug Delivery
- Asthma and respiratory diseases
- Gastroesophageal reflux and treatments
- Hemodynamic Monitoring and Therapy
- Congenital Diaphragmatic Hernia Studies
- Neurosurgical Procedures and Complications
- Cardiac Arrest and Resuscitation
- Neurogenesis and neuroplasticity mechanisms
- Medical Imaging and Pathology Studies
- Ion channel regulation and function
Institut d'Investigació Biomèdica de Girona
2016-2025
University of Girona
2016-2025
Hospital Universitari de Girona Doctor Josep Trueta
2013-2024
Hospital Clínic de Barcelona
2010-2024
Ninewells Hospital
2024
Light Prescriptions Innovators (Spain)
2024
University of Dundee
2024
Istanbul University-Cerrahpaşa
2024
Vlaamse Vereniging voor Obstetrie en Gynaecolo
2024
COPE Galway
2024
Bronchiectasis in adults is a chronic disorder associated with poor quality of life and frequent exacerbations many patients. There have been no previous international guidelines.The European Respiratory Society guidelines for the management adult bronchiectasis describe appropriate investigation treatment strategies determined by systematic review literature.A multidisciplinary group representing respiratory medicine, microbiology, physiotherapy, thoracic surgery, primary care, methodology...
There is a need for clear definition of exacerbations used in clinical trials patients with bronchiectasis. An expert conference was convened to develop consensus an exacerbation use research.A systematic review definitions from January 2000 until December 2015 and involving adults bronchiectasis conducted. A Delphi process followed by round-table meeting experts organised reach definition. These came Europe (representing the European Multicentre Bronchiectasis Research Collaboration), North...
Bronchiectasis is a disease of renewed interest in light an increase prevalence and increasing burden on international healthcare systems. There are no licensed therapies, large gaps knowledge terms epidemiology, pathophysiology therapy. The European Multicentre Audit Research Collaboration (EMBARC) Respiratory Society (ERS) Clinical Collaboration, funded by ERS to promote high-quality research bronchiectasis. objective this consensus statement was define priorities From 2014 2015, EMBARC...
Bronchiectasis is one of the most neglected diseases in respiratory medicine. There are no approved therapies and few large-scale, representative epidemiological studies. The EMBARC (European Multicentre Audit Research Collaboration) registry a prospective, pan-European observational study patients with bronchiectasis. inclusion criterion primary clinical diagnosis bronchiectasis consisting of: 1) history consistent bronchiectasis; 2) computed tomography demonstrating Core exclusion criteria...
Background: Although the FACED score has demonstrated a great prognostic capacity in bronchiectasis, it does not include number or severity of exacerbations as separate variable, which is important natural history these patients. Objective: Construction and external validation new index, E-FACED, to evaluate predictive mortality. Methods: The was constructed on basis complete cohort for construction original score, while undertaken with six cohorts from three countries (Brazil, Argentina,...
Bronchiectasis is a heterogeneous, neglected disease with few multicentre studies exploring the causes, severity, microbiology, and treatment of across Europe. This aim this study was to describe clinical characteristics bronchiectasis compare between different European countries.
COPD and bronchiectasis are commonly reported together. Studies report varying impacts of co-diagnosis on outcomes, which may be related to different definitions disease used across studies.
Background International guidelines recommend airway clearance management as one of the important pillars bronchiectasis treatment. However, extent to which is used for people with in Europe unclear. The aim study was identify use patients across different countries and factors influencing use. Methods This a prospective observational using data from European Multicentre Bronchiectasis Audit Research Collaboration (EMBARC) Registry between January 2015 April 2022. Prespecified options were...
Keeping airways clear of mucus by airway clearance techniques seems essential in bronchiectasis treatment, although no placebo-controlled trials or any studies lasting longer than 3 months have been conducted. We evaluate the efficacy ELTGOL (slow expiration with glottis opened lateral posture) technique over a 1-year period patients chronic expectoration randomised trial. Patients were to perform (n=22) placebo exercises twice-daily (ClinicalTrials.gov, NCT01578681 ). The primary outcome...
Asthma is commonly reported in patients with a diagnosis of bronchiectasis.
Background A validated 4-point sputum colour chart can be used to objectively evaluate the levels of airway inflammation in bronchiectasis patients. In European Bronchiectasis Registry (EMBARC), we tested whether would associated with disease severity and clinical outcomes. Methods We a prospective, observational registry adults conducted 31 countries. Patients who did not produce spontaneous were excluded from analysis. The Murray was at baseline follow-up visits. Key outcomes frequency...
The clinical presentation and prognosis of non-cystic fibrosis bronchiectasis are both very heterogeneous.To identify different phenotypes for their impact on prognosis.Using a standardized protocol, we conducted multicenter observational cohort study at six Spanish centers with patients diagnosed before December 31, 2005, 5-year follow-up from the diagnosis. A cluster analysis was used to classify into homogeneous groups by means significant variables corresponding aspects (clinical...
Data on the prevalence of and factors associated with nontuberculous mycobacteria (NTM) in patients non–cystic fibrosis (CF) bronchiectasis are limited. Our aim was to determine isolation NTM this population. We performed a multicenter observational study historical cohorts comprising consecutive non-CF at least 2 sputum samples cultured for over period 5 years. The population included 218 adult (61.9 % women) mean (SD) age 55.7 (16) years 5.1 (3.3) cultures/patient. isolated from 18 (8.3...
Only a small number of patients with IgG subclass deficiencies (IgGSD) have been observed to bronchiectasis. Moreover, in the series bronchiectasis, IgGSD not found at any frequency, and etiology bronchiectasis remains unclear 29 49% cases. Serum concentrations total IgG, IgA, subclasses as well pulmonary function were measured 65 (aged: 10 74 yr) unknown etiology. An ELISA test was performed quantify 1 through 4 using subclass-specific antihuman monoclonal antibodies. estimation healthy...